Angiex Inc, based in Cambridge, MA, is a pioneering biotech company focused on revolutionizing cancer treatment through the development of Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs). Their innovative technology delivers chemotherapeutic payloads directly to the nucleus of tumor cells and tumor blood vessels, offering the potential for highly effective and targeted therapies for solid cancers.
With a strong commitment to addressing the global cancer epidemic, Angiex aims to be part of the solution by developing first-in-class ND-ADCs that target the hallmarks of cancer lethality. Led by world-renowned experts in tumor blood vessel biology, the company's lead asset, AGX101, is poised to enter clinical trials, while a robust pipeline of additional ND-ADCs is in the discovery stage of development.
Generated from the website